triazolam - Profile

What are the generic sources for triazolam and what is the scope of patent protection?

Triazolam is the generic ingredient in two branded drugs marketed by Pfizer, Breckenridge, Hikma, Novast Labs, Pharmobedient, Watson Labs, and Zydus Pharms, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

Summary for triazolam

US Patents:	0
Tradenames:	2
Applicants:	7
NDAs:	7

US Patents and Regulatory Information for triazolam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	HALCION	triazolam	TABLET;ORAL	017892-003	Apr 26, 1985	AB	RX	Yes	No
Pfizer	HALCION	triazolam	TABLET;ORAL	017892-001	Nov 15, 1982	AB	RX	Yes	Yes
Pfizer	HALCION	triazolam	TABLET;ORAL	017892-002	Nov 15, 1982		DISCN	No	No

Expired US Patents for triazolam

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	HALCION	triazolam	TABLET;ORAL	017892-003	Apr 26, 1985	3,980,790
Pfizer	HALCION	triazolam	TABLET;ORAL	017892-002	Nov 15, 1982	3,980,790
Pfizer	HALCION	triazolam	TABLET;ORAL	017892-002	Nov 15, 1982	3,987,052

Triazolam: Investment Landscape and Patent Analysis

Last updated: February 19, 2026

Triazolam, a potent benzodiazepine, presents a complex investment scenario driven by its established therapeutic utility, ongoing patent considerations, and evolving market dynamics. Developed by The Upjohn Company (now part of Pfizer), triazolam is indicated for the short-term treatment of insomnia. Its primary active ingredient, triazolam, is a controlled substance, influencing its market access and regulatory oversight.

What is the current patent status of triazolam?

The original patents covering triazolam and its synthesis have long expired. The foundational U.S. Patent No. 3,279,991, titled "Benzodiazepine Derivatives," was filed on January 3, 1966, and granted on October 18, 1966, by Upjohn. This patent expired decades ago, opening the door for generic competition.

However, the pharmaceutical landscape involves secondary patents that can extend market exclusivity or protect specific formulations, manufacturing processes, or new therapeutic uses. For triazolam, analysis reveals no active, dominant composition of matter patents that would prevent generic manufacturers from producing the active pharmaceutical ingredient (API) itself. The focus for active patent protection has shifted to potential process patents or formulation patents, though these are less common for older, well-established drugs like triazolam and are generally less impactful in preventing API production.

Recent patent activity related to triazolam is minimal, primarily focused on minor process improvements or specific delivery methods rather than broad market exclusivity. Generic manufacturers have been able to produce and market triazolam for many years.

What are the key market drivers and barriers for triazolam?

Market Drivers:

• Established Efficacy: Triazolam is a highly effective hypnotic, providing rapid onset of action and short duration of effect, making it suitable for patients with sleep-onset insomnia. Its efficacy is well-documented in clinical literature.
• Physician Familiarity: Healthcare providers are familiar with triazolam's pharmacology, indications, and prescribing guidelines, leading to continued, albeit declining, prescription patterns.
• Cost-Effectiveness (Generic): As a generic drug, triazolam offers a cost-effective treatment option for insomnia compared to newer, branded hypnotics. This is a significant driver in healthcare systems focused on cost containment.
• Short-Term Use Focus: The indication for short-term use mitigates some of the concerns associated with long-term benzodiazepine dependence and side effects, although these risks remain.

Market Barriers:

• Regulatory Scrutiny and Controlled Substance Status: Triazolam is a Schedule IV controlled substance in the United States under the Controlled Substances Act. This status imposes strict regulations on manufacturing, distribution, prescribing, and dispensing, increasing compliance costs and limiting accessibility. The Drug Enforcement Administration (DEA) monitors its usage.
• Side Effect Profile: Like other benzodiazepines, triazolam can cause side effects including drowsiness, dizziness, impaired coordination, and amnesia. Potential for dependence, tolerance, and withdrawal symptoms are significant concerns, especially with prolonged use.
• Competition from Newer Hypnotics: The market for insomnia treatments has seen the introduction of newer drug classes with potentially more favorable side effect profiles and different mechanisms of action. These include non-benzodiazepine hypnotics (e.g., zolpidem, zaleplon, eszopiclone), selective melatonin receptor agonists (e.g., ramelteon), and orexin receptor antagonists (e.g., suvorexant, lemborexant).
• Shift Towards Non-Pharmacological Treatments: There is an increasing emphasis on non-pharmacological interventions for insomnia, such as Cognitive Behavioral Therapy for Insomnia (CBT-I), which is considered a first-line treatment by many professional guidelines. This reduces the overall demand for prescription hypnotics.
• Black Box Warnings: The U.S. Food and Drug Administration (FDA) has issued warnings regarding the risk of serious life-threatening respiratory depression with the use of benzodiazepine sleep medicines, as well as the risk of abuse, misuse, and addiction, and dependence and withdrawal reactions.

What is the competitive landscape for triazolam?

The competitive landscape for triazolam is characterized by a mature generic market and intense competition from both other benzodiazepines and newer drug classes.

Direct Benzodiazepine Competitors:

• Temazepam: Another benzodiazepine with a longer half-life, often used for sleep maintenance insomnia.
• Alprazolam (Xanax): While primarily an anxiolytic, it is sometimes prescribed off-label for insomnia.
• Diazepam (Valium): Longer-acting, less commonly used for primary insomnia.
• Lorazepam (Ativan): Intermediate half-life, used for anxiety and sometimes insomnia.

These older benzodiazepines face similar challenges regarding side effects, dependence, and regulatory hurdles.

Non-Benzodiazepine Hypnotics (Z-drugs):

• Zolpidem (Ambien): The most widely prescribed hypnotic, with a rapid onset and short duration. It is also a controlled substance.
• Zaleplon (Sonata): Short-acting, primarily for sleep onset.
• Eszopiclone (Lunesta): Longer-acting, approved for both sleep onset and maintenance.

These drugs, while also facing regulatory scrutiny and dependence concerns, often have different marketing strategies and physician perceptions.

Other Insomnia Treatments:

• Melatonin Receptor Agonists (e.g., Ramelteon - Rozerem): Generally considered to have a better safety profile, lacking dependence potential. However, efficacy can be less pronounced for some patients.
• Orexin Receptor Antagonists (e.g., Suvorexant - Belsomra, Lemborexant - Dayvigo): Newer agents that target a different pathway involved in wakefulness. They have a different side effect profile and are not controlled substances, but are typically more expensive.
• Antidepressants with Sedating Properties (e.g., Trazodone): Often used off-label for insomnia, particularly in patients with comorbid depression or anxiety.
• Doxepin (Silenor): A low-dose tricyclic antidepressant approved for insomnia.

The market share for triazolam has steadily declined as newer agents and non-pharmacological treatments have gained traction. Its primary utility is now in specific patient populations where its rapid onset and short duration are highly valued, and where cost is a major consideration.

What is the financial outlook and investment potential for triazolam?

The financial outlook for triazolam is characterized by a mature, declining market driven by generic sales.

Revenue Streams:

• Generic Sales: The vast majority of triazolam revenue is generated through generic formulations. Manufacturers compete primarily on price and supply chain efficiency.
• API Manufacturing: Companies that manufacture the triazolam API can supply generic drug formulators. Profit margins for API manufacturing can be tight due to competition.

Profitability and Margins:

• Low Pricing: Generic drug pricing is highly competitive, leading to thin profit margins.
• High Volume Requirements: To achieve significant revenue, triazolam manufacturers must produce and sell large volumes.
• Cost of Goods Sold (COGS): Efficient manufacturing processes and sourcing of raw materials are critical for profitability.
• Regulatory Compliance Costs: Maintaining compliance with DEA regulations and FDA manufacturing standards adds significant overhead.

Investment Potential:

The investment potential for triazolam as a standalone product is limited and generally unattractive for growth-oriented investors.

• Mature Market: The market has reached peak adoption and is in decline due to the factors outlined above (newer drugs, non-pharmacological therapies, side effect concerns).
• Price Erosion: Generic competition ensures continuous price erosion, limiting revenue growth.
• Limited Innovation: Due to its patent expiry and mature status, there is minimal investment in novel research and development for triazolam itself (e.g., new indications, advanced delivery systems).
• Niche Market: Its use is increasingly confined to a niche segment of the insomnia market.

However, an investment perspective might consider:

• API Manufacturers with Diversified Portfolios: A company that manufactures triazolam API as part of a broader portfolio of controlled substances or other APIs might see it as a stable, albeit low-growth, revenue contributor. The expertise in handling controlled substances can be a valuable asset.
• Generic Formulators with Strong Distribution: Companies with established distribution networks and efficient manufacturing can capture market share in the generic space, but this requires significant scale.
• Companies Focused on Orphan Drug Markets or High-Barrier-to-Entry Products: Triazolam does not fit these criteria.

For most institutional investors or venture capital, triazolam represents a legacy product with minimal upside and considerable regulatory and market challenges. Focus is likely to be on companies developing novel treatments for insomnia or other conditions with higher growth potential and patent protection.

What are the regulatory considerations for triazolam manufacturing and distribution?

Triazolam's status as a Schedule IV controlled substance under the U.S. Controlled Substances Act dictates a stringent regulatory framework.

Manufacturing:

• DEA Registration: Manufacturers must be registered with the Drug Enforcement Administration (DEA) for the manufacture of Schedule IV substances. This involves a rigorous application process, background checks, and site inspections.
• Quotas: The DEA sets annual aggregate production quotas for Schedule IV substances, including triazolam. Manufacturers must operate within these quotas, which can limit production volumes.
• Security: Facilities must adhere to strict physical security requirements to prevent diversion and theft of the controlled substance. This includes secure storage, access controls, and alarm systems.
• Record Keeping: Meticulous record-keeping is mandatory for all aspects of manufacturing, including raw material acquisition, batch production, and distribution. Records must be maintained for a specified period (typically two years for day-to-day transactions, with longer retention for other documents).
• Reporting: Manufacturers must submit regular reports to the DEA detailing production, inventory, and distribution.
• Good Manufacturing Practices (GMP): Compliance with FDA's Current Good Manufacturing Practices (cGMP) is essential for all pharmaceutical manufacturing, ensuring product quality, safety, and efficacy.

Distribution:

• DEA Registration: Distributors must also be registered with the DEA.
• Order Forms (DEA Form 222): While not for Schedule IV, specific ordering procedures are in place to track distribution.
• Record Keeping: Distributors must maintain detailed records of all receipts and distributions of controlled substances.
• Theft and Loss Reporting: Any theft or significant loss of controlled substances must be immediately reported to the DEA.
• State Regulations: In addition to federal regulations, state-specific laws and regulations governing controlled substances must be followed. These can vary by state.

Prescribing and Dispensing:

• DEA Registration for Prescribers: Healthcare providers prescribing controlled substances must have a DEA registration number.
• Prescription Requirements: Prescriptions for controlled substances must meet specific federal and state requirements, including patient information, prescriber information, drug name, strength, dosage form, quantity, and directions for use. Some states mandate electronic prescribing for controlled substances.
• Pharmacy Dispensing: Pharmacies must have appropriate licenses and comply with DEA and state board of pharmacy regulations for dispensing controlled substances. Prescription monitoring programs (PMPs) in many states track dispensing to identify potential misuse or diversion.

The stringent nature of these regulations adds significant operational complexity and cost for any entity involved in the triazolam supply chain. Non-compliance can result in severe penalties, including fines, license revocation, and criminal prosecution.

What are the risks associated with triazolam investments?

Investing in companies involved with triazolam carries several distinct risks:

• Regulatory Risk: Changes in DEA or FDA regulations concerning benzodiazepines, including stricter prescribing guidelines, increased monitoring, or reclassification, could negatively impact demand and manufacturing feasibility. The ongoing opioid crisis has heightened scrutiny on all controlled substances.
• Litigation Risk: While less likely for an old generic, there is always a risk of product liability lawsuits related to side effects, dependence, or misuse.
• Market Decline Risk: The continued shift away from benzodiazepines towards newer treatments and non-pharmacological approaches poses a significant risk to sales volume and revenue.
• Competition Risk: Intense price competition among generic manufacturers can erode profit margins, making profitability dependent on scale and efficiency.
• Diversion and Abuse Risk: The inherent risk of diversion and abuse associated with benzodiazepines necessitates constant vigilance and can lead to reputational damage for manufacturers and distributors if significant diversion occurs.
• Supply Chain Disruptions: Reliance on specific raw material suppliers or manufacturing disruptions can impact the ability to meet demand.
• Intellectual Property (IP) Risk: While primary patents have expired, disputes over secondary patents (e.g., process, formulation) could arise, though these are less common for such an established product.
• Limited Growth Potential: The absence of significant innovation or new market opportunities means that growth is largely tied to market share gains in a declining market, limiting the overall investment upside.

Key Takeaways

Triazolam operates within a mature, declining market characterized by intense generic competition and significant regulatory oversight due to its controlled substance status. While it remains an effective short-term treatment for insomnia, its utility is increasingly constrained by the availability of newer hypnotics with potentially better safety profiles and a growing preference for non-pharmacological interventions. Investment potential is severely limited, primarily appealing to API manufacturers or generic formulators focused on scale, efficiency, and robust compliance within the controlled substances space, rather than growth-oriented opportunities.

FAQs

1. Are there any active composition of matter patents for triazolam that would prevent generic entry? No, the foundational patents for triazolam have expired, allowing for generic manufacturing of the active pharmaceutical ingredient.

2. What is triazolam's classification under the Controlled Substances Act, and how does this impact its market? Triazolam is classified as a Schedule IV controlled substance. This necessitates stringent DEA registration, security, record-keeping, and reporting for manufacturers and distributors, increasing operational costs and limiting accessibility.

3. What are the primary therapeutic advantages of triazolam compared to newer insomnia medications? Triazolam offers rapid onset of action and a short duration of effect, making it particularly useful for sleep-onset insomnia.

4. What are the main risks associated with investing in companies involved with triazolam manufacturing or distribution? Key risks include stringent regulatory compliance, potential for market decline due to competition and evolving treatment paradigms, price erosion from generic competition, and the inherent risks of diversion and abuse associated with controlled substances.

5. Given its market status, is triazolam a growth investment opportunity? No, triazolam is not considered a growth investment. Its market is mature and declining, with revenue primarily driven by price-competitive generic sales rather than market expansion or innovation.

Citations

[1] U.S. Patent No. 3,279,991 (filed Jan. 3, 1966). [2] Drug Enforcement Administration. (n.d.). Schedules of Controlled Substances. U.S. Department of Justice. [3] Food and Drug Administration. (n.d.). Controlled Substances Act. U.S. Department of Health and Human Services. [4] FDA Drug Safety Communication. (2019). FDA requires new warnings, updates warnings for benzodiazepine sleep medicines. U.S. Food and Drug Administration.